Drugs / CD19 CAR-DC
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05585996 | Aug 2022 → Nov 2025 | B-cell non-Hodgkin lymphoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19 CAR-DC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05585996 ↗ |
| Modality | Cell therapy | “CAR DC cells” NCT05585996 ↗ |
| Route | Intravenous | “Intravenously injected CAR DC cells and followed by CAR T cells 4 hours later” NCT05585996 ↗ |
| Target | CD19 | “CD19-targeted CAR-T and CAR-DC” NCT05585996 ↗ |